TOP > 外国特許検索 > DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME

DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME NEW コモンズ

外国特許コード F190009992
整理番号 (FU789)
掲載日 2019年10月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP009522
国際公開番号 WO 2019188151
国際出願日 平成31年3月8日(2019.3.8)
国際公開日 令和元年10月3日(2019.10.3)
優先権データ
  • 特願2018-066043 (2018.3.29) JP
発明の名称 (英語) DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME NEW コモンズ
発明の概要(英語) A data acquisition method according to the present invention is used for the purpose of using a clinical urine sample to simply and noninvasively detect whether the cell cycles of kidney-derived cells have progressed from the G2 phase to the M phase. This data acquisition method is for determining whether the cell cycles of kidney-derived cells in a subject have progressed from the G2 phase to the M phase and includes a step for detecting thioredoxin in urine collected from the subject.
従来技術、競合技術の概要(英語) BACKGROUND ART
Renal failure, morbidity, and, a poor prognosis of diseases and, particularly, severe acute renal failure (acute kidney injury: AKI) is, the mortality rate is greater than 50%.
Conventionally, kidney failure (for example, acute renal failure) diagnosis, an amount of change in serum creatinine, and/or, based on the change in the amount of urine are carried out. However, the serum creatinine, renal failure 2-3 days occurs after the change from the amount for the biomarker, based on the change in the amount of serum creatinine diagnosed of renal impairment, delay the beginning of the treatment of renal impairment, as a result, tends to be a poor prognosis.
Therefore, when a failure occurs in an early stage renal from the resulting change in the amount of the biomarker and, L-FABP(L type fatty acid binding protein), NGAL(neutrophil gelatinase associated lipocalin), TIMP-2(tissue inhibitor of metalloproteinase-2), IGFBP7(insulin-like growth factor-binding protein 7), renal dysfunction (for example, acute renal failure) are used to diagnose (see Non-Patent Document 1 and 2). TIMP-2, and, is IGFBP 7, from G1 phase to phase S from renal cell in the cell cycle progression of the presence or absence of the biomarker can be detected.
Incidentally, in recent years, acute renal failure from the transition of chronic kidney disease, kidney epithelial cells from the G2 phase of cell cycle progression to the phase M is stopped and, from stage G2 to stage in the kidney epithelial cells M with the stop of the cell cycle progression of the tubules and interstitial fibrosis, is related has been suggested (see Non-Patent Document 3).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF FUKUI
  • JJAPAN BIOSTRESS RESEARCH PROMOTION ALLIANCE
  • 発明者(英語)
  • KASUNO, Kenji
  • IWANO, Masayuki
  • YODOI,Junji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close